"PIK"ing the Right Patients for Adjuvant Aspirin Therapy for Colorectal Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 40439583.
- Also identified by DOI 10.1158/1078-0432.CCR-25-0953.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Observational studies demonstrate that aspirin use after diagnosis of colorectal cancer, particularly tumors with mutated PIK3CA, improves outcomes. However, randomized controlled trial data are lacking. In this issue, we discuss the SAKK 41/13 adjuvant aspirin randomized controlled trial results in context of other adjuvant aspirin trials and emerging data on potential mechanisms of action. See related article by Güller et al., p. 3142.
Medical subject headings
- Aspirin
- Colorectal Neoplasms